VivoSeq
Metabolic & Endocrine

NASH

3

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

NASH is an early-stage landscape with 3 programs across 5 companies. The most active players are Madrigal Pharmaceuticals, Eli Lilly, GSK. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Madrigal Pharmaceuticals logo

Madrigal Pharmaceuticals

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3GSK logo

GSK

0 programs

PreclinicalH

Hepion Pharmaceuticals, Inc.

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

K-877-ER

Kowa Research Institute, Inc.

CSG452

Kowa Research Institute, Inc.

Phase 31

Resmetirom

Madrigal Pharmaceuticals

Approved
No programs

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Recruiting3 · 20%
Unknown status1 · 7%
Terminated1 · 7%
Withdrawn1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Digoxin In NASH (CODIN)
Recruiting·YYale University·Phase 2·NCT06588699·144 enrolled
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Recruiting·UUniversity of Florida·Phase 2·NCT04501406·166 enrolled
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Recruiting·PPolaris Group·Phase 2·NCT05842512·60 enrolled
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)
Active, not recruiting·Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals·Phase 3·NCT05500222·845 enrolled
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
Completed·GSK logoGSK·Phase 2·NCT06104319·61 enrolled
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Completed·CCellaion SA·Phase 1/2·NCT03963921·23 enrolled
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 3·NCT01051219·45 enrolled
Study to Evaluate MET642 in Patients With NASH
Completed·MMetacrine, Inc.·Phase 2·NCT04773964·215 enrolled
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
Completed·HHepion Pharmaceuticals, Inc.·Phase 2·NCT04480710·47 enrolled
CM-101 in NASH Patients - The SPLASH Study
Completed·CChemomAb Ltd.·Phase 2·NCT05824156·23 enrolled
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT03166735·114 enrolled
Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Participants With Noncirrhotic Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
Completed·KKowa Research Institute, Inc.·Phase 2·NCT05327127·228 enrolled
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Terminated·SSeoul St. Mary's Hospital·Phase 4·NCT01406704·26 enrolled
Feasibility Study for Quantifying Fatty Liver Using Thermo-acoustic Imaging
Withdrawn·MMedical College of Wisconsin·N/A·NCT04302051
Norursodeoxycholic Acid vs. Placebo in NASH
Unknown status·—·Phase 2·NCT05083390·363 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)